Navigation Links
Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation

TARRYTOWN, N.Y., Sept. 25 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) has agreed to accept $18 million from Eli Lilly and Company (NYSE: LLY) to settle the pending litigation between the two companies.

The parties will promptly submit a Stipulation of Dismissal with Prejudice of their litigation to the United States District Court for the Southern District of Indiana. Additional terms and conditions of the settlement are confidential. Emisphere will recognize the settlement net of attorneys' fees and expenses.

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology. These molecules and compounds could be currently available or are in pre-clinical or clinical development. Such molecules or compounds usually cannot be delivered by the oral route of administration or the benefits of these compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The Web site is:

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758) and for the quarter ended June 30, 2007, filed on August 7, 2007 (file No. 000-17758).

SOURCE Emisphere Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. Georgia stem cell company likely to stay put
3. Surgical products company wins Governors Business Plan Contest
4. Madison stem cell company gets $1M from state
5. Company still behind schedule on Milwaukee wireless project
6. Software company enters health space with RFID solutions on hold
7. Delaware company will keep NameProtect here
8. IPO-bound NimbleGen traveling in fast company
9. Wisconsin tries to woo another stem cell company
10. Company to operate in wireless Internet space
11. RedPrairie acquires Denver software company
Post Your Comments:
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... of a new closed system for isolating adipose-derived stem cells. The announcement starts a ... of adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction of ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced the opening ... the cities of Arica and Iquique in northern Chile. The facilities are part of GSCG’s ... most advanced protocols and techniques in stem cell medicine to patients from around the world. ...
(Date:11/30/2015)... (NYSE: BIOA ), a leader in renewable materials, today ... Climate Pledge, alongside more than 140 companies from across the ... demonstrate an ongoing commitment to climate action and to voice ... Paris climate negotiations. Sarnia, Canada ... --> BioAmber uses biotechnology to convert renewable sugars ...
Breaking Biology Technology:
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):